Daily Stock List
ChineseInvestors.COM, Inc. (CIIX)
FeedBlitz, RollingStocks.com, NicksPennyPicks.com, HotPennyStocksToday, RockingStocks.com, and Featured Profiles reported earlier on ChineseInvestors.COM, Inc. (CIIX), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Established in 1999, ChineseInvestors.COM, Inc. is a provider of business and financial news in China. They provide real-time market commentary and analysis in the Chinese language. They deliver this through their websites (www.chinesefn.com and www.chineseinvestors.com) to Chinese persons globally. Their website presents analysis, commentary, research tools, and computer generated quantitative analysis to provide their subscribers and users a view of the global financial markets. ChineseInvestors.COM has their headquarters in Arcadia, California.
ChineseInvestors.COM offers timely market information of U.S. publicly traded stocks and foreign currencies. They provide free quotes, charts, market news, and links to research. The design of ChineseInvestors.COM is for Chinese Investors who are looking for trustworthy market information to help them make informed investment decisions.
ChineseInvestors.COM offers several types of subscription-based services and they serve several levels of investors and traders, from novice to professional. Chinese speaking individuals living in North America primarily use the Company's services. The Company also provides contract client support & sales services, consulting services for private companies (U.S. and international) considering public options in the U.S., advertising and PR/IR services, and other related financial service and education based products.
The subscription services that the Company offers include VIP Golden Membership; Education Materials (Video Training); Option Investment & Trading; US Market Megatrend Software, and China Market Megatrend Software. In addition, services offered include FOREX (Foreign Currency Exchange); Dark Horse; Chinese Momentum Stock; Analysis on News and earnings Internet Concept Stocks, and The Five Most-Bullish Stocks as well as diverse free analysis and research tools.
Their business model currently requires that all of their product lines generate recurring monthly revenue from each client relative to 'client specific' contract services duration. This is typically provided on a monthly, quarterly, or yearly basis that incorporates discounts for longer duration commitments.
This week, ChineseInvestors.COM announced that Mr. Brett Roper, the Chief Operating Officer (COO) of the Company conducted an online interview with Wall Street Newscast, regarding their recent launch of their financial news television program in China and the Company's outlook for 2013. The interview covered topics such as the Company's partnership with CBN iTV, and Shanghai Media Group, regarding the launch of their daily one-hour financial news TV program covering the U.S. markets in Shanghai, China, and their improving earnings outlook.
ChineseInvestors.COM, Inc. (CIIX), closed Friday at $0.59, up 20.41%, on 2,200 volume with 2 trades. The average volume for the last 60 days is 3,291 and the stock's 52-week low/high is $0.35/$3.88.
BioZone Pharmaceuticals, Inc. (BZNE)
Today we are highlighting BioZone Pharmaceuticals, Inc. (BZNE), here at the QualityStocks Daily Newsletter.
Incorporated under the laws of the State of Nevada on December 4, 2006, BioZone Pharmaceuticals, Inc. is a pharmaceutical company that specializes in drug development, manufacturing, and marketing. The Company has developed proprietary drug delivery technology that has enabled and revolutionized the administration of drugs that are difficult to formulate. Flagship products of BioZone include the GlyDerm dermatological care line and P&S Liquid and Shampoo. BioZone Pharmaceuticals has their corporate headquarters in Englewood Cliffs, New Jersey.
On May 16, 2011, BioZone acquired substantially all of the assets and assumed all of the liabilities of Aero, pursuant to an Asset Purchase Agreement dated as of that date. Aero manufactures, markets, and distributes a line of dermatological products under the trade name of Baker Cummins Dermatologicals.
On June 30, 2011, BioZone acquired the BioZone Lab Group, which operates as a developer, manufacturer, and marketer of Over-The-Counter (OTC) drugs and preparations, cosmetics, and nutritional supplements. They do this on behalf of health care product marketing companies and national retailers. BioZone has also been developing their proprietary drug delivery technology as an enhancement for approved, generic prescription drugs that are limited due to poor stability or bioavailability or variable absorption.
The application of the Company's technology allows them to pursue reformulation of generic drugs and pursue a low-risk regulatory pathway for NDA approval. BioZone Pharmaceuticals also provides oral, topical, and injectable drug products for anesthesia, infectious diseases, metabolic diseases, and oncology. They offer a unique line of dermatology products for an assortment of dermatological diseases.
BioZone's GlyDerm is a dermatologist recommended regimen to improve skin health and appearance. Each product uniquely compliments a dermatologist-applied peel and helps in the skin-improvement process.
The Company's P & S liquids are a unique coal tar solution shampoo for the treatment of psoriasis. The auxiliary products all work together to treat extreme dryness and flaking in the skin. They do this without leaving unsightly and sticky residue behind.
BioZone Pharmaceuticals, Inc. (BZNE), closed Friday's trading at $3.00, up 33.33%, on 200 volume with 2 trades. The average volume for the last 60 days is 728 and the stock's 52-week low/high is $0.51/$4.00.
Novation Holdings, Inc. (NOHO)
We are highlighting Novation Holdings, Inc. (NOHO), here at the QualityStocks Daily Newsletter.
Novation Holdings, Inc., formerly Allezoe Medical Holdings, Inc., engages in the business of acquiring and managing operating companies. They are doing this initially in the medical device development and production market, and subsequently in other healthcare, technology and similar markets. Novation Holdings is based in Boca Raton, Florida. The Company lists on the OTC Bulletin Board.
In addition, Novation Holdings is focusing on other related acquisitions in the medical device field, as well as in other market segments. The Company has entered into a licensing agreement, through SureScreen Medical, Inc., with AVM Corp. for the licensing of technology that would enable healthcare providers to see and treat human papillomavirus (HPV), a sexually transmitted infection and a cause of cervical cancer.
Earlier this month, Novation Holdings announced that they acquired Burgoyne Internet Services, LLC, a profitable Internet service provider based in Utah. The transaction was completed on December 6, 2012, with an effective date for accounting purposes of November 30, 2012. The selling group also agreed to provide working capital to Novation. Burgoyne Internet Services provides Internet access, emails, and related services to customers throughout the U.S. This is mainly in areas where high-speed cable and other high-speed Internet access services are not readily available.
Yesterday, Novation Holdings (NOHO) announced that their stock trading symbol has been changed by FINRA to NOHO from the prior symbol ALZM, effective December 20, 2012. Because of the recent (November 6, 2012) effective date of the name change, reverse split and change of corporate domicile, the trading symbol for the common stock changed as of November 6, 2012 to "ALZMD" to signify the completion of the reverse split and the issuance of a new CUSIP number for the common stock.
On December 6, 2012, the "ALZMD" trading symbol was changed back to "ALZM" by FINRA, the same as before the effective date. The new trading symbol NOHO, which represents the new Novation Holdings name, was issued by FINRA on December 19, 2012.
Novation Holdings, Inc. (NOHO), closed Friday's trading session at $0.0241, down 36.58%, on 201,857 volume with 9 trades. The average volume for the last 60 days is 1,157 and the stock's 52-week low/high is $0.0201/$0.6597.
Discount Dental Materials, Inc. (DDOO)
Today we are reporting on Discount Dental Materials, Inc. (DDOO), here at the QualityStocks Daily Newsletter.
Discount Dental Materials, Inc. engages in the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. The Company's planned products include a medical device solution and a synthetic drug solution. The Company conducts their operations through their wholly owned subsidiary Cerebain Biotech Corp. Incorporated in Nevada on December 17, 2007, Discount Dental Materials lists on the OTCBB.
Incorporated in 2010, Cerebain Biotech, an early-stage drug development enterprise, engages in the development and commercialization of targeted treatments for Alzheimer's disease. This subsidiary develops disease-arresting biological agents using Omentum, which is naturally found in the human body. United States Patent Application Serial No. 12/361-808, takes a novel approach by developing a disease-arresting drug compared to the current disease-inhibitors that are available today. Cerebain has the exclusive global license rights for the Patent.
Clinical studies have proven that Omentum has biological agents that are regenerative. These agents exercise a favorable affect on the human brain. Cerebain Biotech's approach taps the Omental tissue without major surgery. Their Patent describes various methods of harvesting this agent from Omentum and administering it to the patients. It covers all potential ways of extracting the "brain booster". The Patent also covers groundbreaking methods of administering it to patients.
The long-term business plan of the Company's Cerebain subsidiary is to explore the biochemical nature of this neurotrophic agent by basic research; develop medical devices described in the Patent, to continuously deliver the "brain booster" for sustained effect, and develop an injectable form of this agent.
This past October, Cerebain Biotech announced that medical device product development company, Sonos Models, Inc., completed Phase 1A of their medical device solution. They will commence Phase 1B, which will research the Omentum and related patents and literature to obtain a better understanding of the Omentum as a basis for designing the fluid extraction device. Sonos Models has provided industrial design services for 30 years to a broad range of customers. These include the consumer products, toy, manufacturing, and medical industries.
Discount Dental Materials, Inc. (DDOO), closed Friday's trading session at $1.01, up 102.00%, on 100 volume with 1 trade. The average volume for the last 60 days is 1,994 and the stock's 52-week low/high is $0.13/$2.99.
Liberty Gold Corp. (LBGO)
FeedBlitz, Whisper from Wall Street, The Best Newsletters, AnotherWinningTrade, Stock Research Newsletter, Investment House, and Market FN reported earlier on Liberty Gold Corp. (LBGO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Based in Phoenix, Arizona, Liberty Gold Corp. is a gold and precious metals exploration company. Their ongoing property acquisition strategy targets regions with proven gold and silver resources and industry-friendly business environments. Their project portfolio includes the Domestic Portfolio in Arizona and the McCord Creek Property in Alaska. The Company's shares trade on the OTC Bulletin Board.
Liberty Gold has a 100 percent interest in the 794-acre Domestic Portfolio mining operations claim block. It is located in the Cerbat Mountain range, approximately 75 miles southeast of Las Vegas and 15 miles northwest of Kingman in northwestern Arizona's Wallapai Mining District. In August 2012, Liberty Gold announced positive results following initial sampling and processing for visible gold on their Domestic Portfolio. The Domestic Portfolio consists of 40 individual projects; they range in size from 16 to 20 acres each. The project also consists of four patented mining claims, 11 Federal mining claims (unpatented), as well as 25 pure exploration prospects.
Liberty Gold's ongoing 2012 McCord Creek Property work program has collected and submitted 333 samples for analysis. The objective is defining drill targets for the 2013 field season. In October 2012, Liberty Gold reported on International Tower Hill's (ITH) August 21, 2012 announcement of new, high-grade gold intercepts surrounding ITH's main deposit at their Livengood Gold Project in Alaska. ITH's Livengood Property immediately adjoins the western side of Liberty Gold's 4,620-acre McCord Creek Property.
The Money Knob deposit on ITH's Livengood Property represents a resource estimate of 16.5 million ounces (Moz) Measured & Indicated at 0.22 grams per tonne cut-off, making it one of the largest gold deposits discovered in 20 years. Liberty Gold's McCord Creek Property consists of 33 State mining claims. Liberty Gold will be the project operator. The property is situated 70 miles northwest of Fairbanks in the Tintina Gold Belt.
Liberty Gold Corp. (LBGO), closed Friday's trading session at $0.199, up 4.19%, on 8,328 volume with 4 trades. The average volume for the last 60 days is 37,315 and the stock's 52-week low/high is $0.191/$1.15.
Massive Dynamics, Inc. (MSSD)
Real Pennies, SmallCapNetwork, Investor Spec Sheet, SmallCapVoice, Wallstreet Profiler, PennyDoctor, Wallstreetbuzz, and MajorPennyStocks reported this month on Massive Dynamics, Inc. (MSSD), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
Massive Dynamics, Inc. is an acquirer, developer and seller of leading edge communications technology and products. The Company primarily focuses on the profitability of the oncoming universal Web 4.0 technologies. Currently, Massive Dynamics is planning to announce several Web 4.0 product advances over the next 12 months. The Company is based in Cupertino, California. Their shares trade on the OTC Bulletin Board.
Web 4.0 centers mainly around systems that involve "Intelligent Interaction" with users. Massive Dynamics is integrating DYNAMIC KEYSET in Android applications and technology that will allow the use of glass surfaces to be used for Intelligent Interaction. The Company also offers their TeliPad smartphone product.
Massive Dynamics believes that DYNAMIC KEYSET could significantly expand teacher and student Intelligent Interaction. They believe it would have near endless intelligent interaction between workers, management, computing devices and presentation devices. For Home use, there are many applications for Intelligent Interaction on glass surfaces using DYNAMIC KEYSET.
In addition, Massive Dynamics has developed the RANGER MD8. It utilizes biquad antenna technology for quality wireless signal to 8 miles away. This Product can be used in outlying areas to reach urban wireless early - or any applications in which a long-range remote receiver is needed.
This week, Massive Dynamics disclosed that the first shipments of "glossy white" versions of the Company's TeliPad smartphone product arrived while the Company is currently focusing on preorder fulfillment. The TeliPad product represents Massive Dynamics' entry into the multi-billion dollar smartphone market. The TeliPad smartphone device adds a two-line cellular phone to an existing Apple iPad, Android tablet or Windows tablet. This does away with the need to carry a separate smartphone. The Company has indicated that they have experienced a surprising number of preorders since Cyber Monday of this holiday season.
The TeliPad is approximately the size of a credit card. It can be fastened to the back of a computing tablet or kept in close proximity; it works by way of Bluetooth©. The TeliPad is compatible with iOS, Android and Windows tablets. The design of the smartphone function is to work on AT&T©, Verizon©, T-Mobile©, and Cellular One© networks or any network that supports SIMM. Currently, the TeliPad is not supported by Sprint© network systems technology.
Massive Dynamics, Inc. (MSSD), closed Friday's session at $1.37, up 16.10%, on 62,533 volume with 146 trades. The average volume for the last 60 days is 52,689 and the stock's 52-week low/high is $0.0492/$2.08.
Longreach Oil & Gas Ltd. (LOI.V)
Today we are reporting on Longreach Oil & Gas Ltd. (LOI.V), here at the QualityStocks Daily Newsletter.
Longreach Oil & Gas Ltd. is an independent oil and gas exploration company whose shares trade on the TSX Venture Exchange. Incorporated in Jersey, Channel Islands, the Company's strategy includes a regional focus within North Africa. Longreach's administrative office is in London, England. Established in April of 2006 by founding Chairman and Director, Mr. Bryan Benitz, their commitment is to Morocco as their core company focus. Morocco is the second largest energy importer in Africa. Longreach has a portfolio of near term development and high reward exploration.
Longreach Oil & Gas has significant exploration acreage. The Company's technical team has over 30 years of geological experience within Morocco. Their management team has direct and personal relationships at the highest levels of the Moroccan Natural Resource Ministry.
The Company's corporate strategy includes a strict regional focus and the acquisition of the most promising licenses. Their strategy is to enhance exploration licenses by way of geophysical work programs. Furthermore, their strategy includes the identification of drill targets, and building value through timely monetization.
Longreach's operations include Onshore, Sidi Moktar; Onshore, Zag Basin; Onshore, Tarfaya, as well as Offshore, Sidi Moussa & Foum Draa. Longreach has a 50 percent Working Interest and is Operator of the Sidi Moktar licenses. Sidi Moktar consists of three blocks totaling 4,711 square kilometers. It is located within the Essaouira Basin in central Morocco.
The Company has a 22.5 percent Working Interest in the Zag Exploration License. Located in Southern Morocco, Zag covers an area of 21,807 square kilometers (5.39 million acres). Longreach has a 22.5 percent Working Interest in the Tarfaya Exploration License. Located in Southern Morocco, Tarfaya covers an area of 13,434 square kilometres (3.32 million acres).
Sidi Moussa and Foum Draa are two contiguous licenses. They are situated offshore Morocco, directly west of Agadir. They cover an area of 12,714 square kilometers (3.14 million acres). Longreach Oil & Gas has a 7.5 percent Working Interest in both of these licenses.
Longreach Oil & Gas Ltd. (LOI.V), closed Friday's session at $0.70, up 6.06%, on 46,700 volume. The stock's 52-week low/high is $0.41/$1.00.
Syntroleum Corp. (SYNM)
Investor Ideas, SmarTrend Newsletters, Alternative Energy, Wall Street Resources, Investor Update, and Greenbackers reported earlier on Syntroleum Corp. (SYNM), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Tulsa, Oklahoma, Syntroleum Corp. produces synthetic fuels from a wide array of feedstock - from natural gas to fats, oils and greases. They own the Syntroleum® Process for Fischer-Tropsch (FT) conversion of synthesis gas into liquid hydrocarbons, the Synfining® Process for upgrading FT liquid hydrocarbons into refined petroleum products, and the Bio-Synfining® technology for converting renewable feedstocks into drop-in fuels.
Founded in 1984, Syntroleum has a 50 percent interest in Dynamic Fuels, LLC. Dynamic Fuels operates a 75 million gallon per year renewable fuels facility located in Geismar, Louisiana using their Bio-Synfining® technology. Syntroleum's goal is to be the leading provider of Fischer-Tropsch and related technologies for the production of synthetic fuels. Their business strategy to achieve this goal involves participating in development projects, licensing the Syntroleum Processes, and expanding and developing product markets.
The Fischer-Tropsch process has already been used through Syntroleum's all-inclusive labs and production facilities to produce substantial amounts of synthetic diesel and jet fuel. These fuels have been successfully proven to perform better than conventional fuels across nearly all operating parameters, including emissions, thermal stability, and cetane.
Syntroleum's Fischer-Tropsch and Synfining® processes are suited to produce ultra-clean, renewable fuels from biomass; Syntroleum is pursuing projects in this area. Their Fischer-Tropsch GTL technology makes it possible for the Company to produce gas onshore and in marine environments. Their process realizes the advantages of building a plant on a significantly smaller footprint. This allows for economic development of fields in the one-to-three trillion cubic feet range, a number of them in remote locations. The Company's process additionally represents a solution to flaring.
Last month, Syntroleum announced financial results for the nine months ended September 30, 2012. For the nine months ended September 30, 2012, they reported operating income of $10.0 million resulting from total revenues of $16.4 million and operating expenses of $6.4 million.
Syntroleum's net loss was $1.0 million or $0.01 per share for the three months ended September 30, 2012, and net income of $4 million or $0.04 per share for the nine months ended September 30, 2012. This is in comparison with net losses of $4.6 million or $0.05 per share and $14.0 million or $0.16 per share for the corresponding periods in 2011. As of September 30, 2012, the Company's available cash position was $17.6 million.
Syntroleum Corp. (SYNM), closed Friday's trading session at $0.35, down 3.54%, on 633,239 volume with 635 trades. The average volume for the last 60 days is 241,918 and the stock's 52-week low/high is $0.37/$1.539.
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.032, up 6.67%, on 2,100,978 volume with 62 trades. The stock’s average daily volume over the past 60 days is 1,871,058, and its 52-week low/high is $0.0283/$0.179.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
Advaxis Presents at NYC MedTech Program
Advaxis Updates Phase 2 Cervical Cancer Trial Data
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.21, up 6.38%, on 341,780 volume with 56 trades. The stock’s average daily volume over the past 60 days is 121,070, and its 52-week low/high is $0.161/$0.68.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
Lifeline Skin Care a Subsidiary of ISCO Announces New Sales and Multi-Media Marketing Campaigns
German Court Decision May Strengthen International Stem Cell Corporation's Position in European Market
International Stem Cell Corp to Participate in Fifth Annual LD Micro Conference
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.06, up 9.09%, on 142,200 volume with 5 trades. The stock’s average daily volume over the past 60 days is 49,624, and its 52-week low/high is $0.0069/$0.07.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Appoints Dennis Raefield as Chief Operating Officer
Viscount Announces Completion of $500,000 Private Placement
Viscount Systems Wins Contract with Phoenix Sky Harbor Sky Train
The Guitammer Company Inc. (GTMM)
The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.16, up 6.67%, on 7,600 volume with 3 trades. The stock’s average daily volume over the past 60 days is 13,953, and its 52-week low/high is $0.082/$0.35.
The Guitammer Company Inc. (GTMM) is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.
The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.
Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.
Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment. Disclaimer
The Guitammer Company Inc. Company Blog
The Guitammer Company Inc. News:
Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
Guitammer Third Quarter Revenue More Than Triples To $555,000
Guitammer CEO Mark Luden to Present at 7th Annual Singular Research 'Best of the Uncovereds' Conference in Los Angeles
One of the hottest areas in medical technology today is the rapidly growing field of immunotherapy, the manipulation of the body’s own immune system to target and combat cellular based diseases such as cancer. The key to immunotherapy, and the biggest challenge, is to develop a mechanism for interacting with and controlling the body’s immune system that is both safe and effective.
Advaxis, a New Jersey based biotechnology company focused on immunotherapies for cancer and infectious diseases, is utilizing a unique platform technology under exclusive license from the University of Pennsylvania, based upon the work of Yvonne Paterson, Ph.D., Professor of Microbiology. The technology utilizes a live attenuated bacterium, Listeria monocytogenes (Lm), bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Her work has shown that Lm-LLO based immunotherapies stimulate the immune system to induce antigen-specific anti-tumor immune responses involving both innate and adaptive arms of the immune system. In addition, this technology could facilitate the immune response by altering the microenvironment of tumors to make them more susceptible to immune attack.
The company’s initial focus has been on immunotherapies targeting HPV-associated diseases, specifically cervical intraepithelial neoplasia (CIN 2/3), recurrent or refractory cervical cancer, as well as head and neck cancer. In addition, they have developed immunotherapies for prostate cancer and HER2 expressing cancers, such as breast, gastric, bladder, brain, pancreatic, and ovarian cancer.
Advaxis has more than fifteen constructs in various stages of development, with their lead construct, ADXS-HPV, currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. In April, 2012, ADXS-HPV was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
For additional information, visit www.Advaxis.com
Today, Atossa Genetics announced that Christopher S. Destro has joined the company as its new Vice President of Sales and Marketing. An industry veteran with over 16 years of successful sales and client management expertise, Mr. Destro will oversee product marketing, distribution, and sales. He will report to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President.
“[Atossa] is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time,” remarked Dr. Quay. “As we accelerate the national roll-out of our ForeCYTE and ArgusCYTE Breast Health Tests in early 2013, Chris’ extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives.”
From 2007 to 2011, Mr. Destro held multiple prominent positions, including Vice President of Sales, North America, for three divisions of Magellan Biosciences where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex, and a lead care platform for Point of Care testing. In July 2011, Thermo Fisher Scientific acquired Magellan, and Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. From 2000 to 2007, Mr. Destro served as Americas Sales Director for International Bioproducts, managing sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.
Mr. Destro said, “Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company’s products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women’s lives. Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa’s growth as we expand the commercialization of our innovative products and services in the U.S.”
He continued, “One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever.”
On December 20, 2012, as incentive to join the company, Mr. Destro was awarded an option to purchase a total of 200,000 shares of Atossa’s common stock, par value $0.001 per share, outside the company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date, and vests over a four-year period from his commencement of service.
For more information on Atossa Genetics, visit www.atossagenetics.com
ZBB Energy, a leading developer of intelligent power and energy management technologies, announced that it will be joining the National Alliance for Advanced Technology Batteries (NAATBatt). The alliance will be holding an Annual Conference and Symposium on January 16-18, 2013, in Austin, Texas, where ZBB Energy will present “Ensuring Reliable Power in Unreliable Environments,” which highlights the enabling capabilities of ZBB’s comprehensive power control and energy storage technologies.
NAATBatt is a not-for-profit trade association of foreign and domestic corporations, associations, and research institutions focused on the manufacture of large format advanced batteries for use in transportation and large scale energy storage applications in the United States. Members range from advanced battery and electrode manufactures to material suppliers, vehicle makers, electric utilities, equipment vendors, service providers, universities, and national laboratories.
NAATBatt’s core missions are to grow the North American market for products incorporating advanced energy storage technology and to reduce the cost of those products to U.S. consumers. The core missions of NAATBatt are closely related. NAATBatt operates under the principal that the high cost of electrochemical energy storage, when compared to other technologies, serves as the primary barrier to widespread adoption of large format advanced battery technology. NAATBatt advocates for the adoption of public policies and the development of new technologies and industrial standards that will help reduce the cost to consumers of large format advanced batteries and the products that use them.
NAATBatt provides a platform for its members to work together across industry boundaries in order to address the challenges posed by the adoption of large scale electrochemical energy storage. NAATBatt programs aid in the advancement of energy storage technology and help promote best practices among industry members. NAATBatt helps make the advanced battery industry more efficient and successful by sharing networking opportunities and better information about the North American market for those companies that wish to serve it.
For more information on ZBB Energy, visit www.zbbenergy.com
Few would argue that a foundational key to building a business is developing the ability to take a great product or service and to expand it into new forms and markets, but without losing sight of the intrinsic qualities that made the product great in the first place. In the case of Noble Roman’s, which started as a popular pizzeria on the campus of Indiana University back in 1972, it’s always been about maintaining the quality of their food. The company now operates over 1,700 franchsed/licensed outlets throughout the U.S., as well as in Puerto Rico, the Bahamas, Canada, and even Italy. Their food now includes everything that it takes to make great pizza, in addition to breadsticks and cheesesticks, chicken wings, salads, pasta, sandwiches, and even breakfast items.
It wasn’t until the late 1990s that the company decided to go from just operating a string of quick-service pizza restaurants to developing the technology required to operate in numerous types of non-traditional venues, while maintaining the product quality that their extensive fan-base demanded. Today the company provides the best pizza and sub sandwich foodservice products and systems to individual franchisees, but also to entertainment facilities, convenience stores, bowling centers, universities, and military bases.
This includes supplying take-n-bake pizzas to convenience stores as well as a stand-alone offering for grocery stores. One of their fastest growing venues is in groceries, where they provide a deli-based take-n-bake pizza program complemented with other made-for-home retail products. The company, now a multi-million dollar business, continues to see growth in revenue, operating margins, and net income, but remains committed to product quality and taste as the foundation that supports everything else.
For additional information, visit www.NobleRomans.com
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News